NCCN Awards Grants to Three Researchers to Investigate Volasertib in Hematologic Malignancies

The NCCN Oncology Research Program has awarded three research grants to investigate the safety and effectiveness of volasertib in hematologic malignancies. FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has awarded three grants to investigators from NCCN Member Institutions to scientifically evaluate and define the safety and clinical effectiveness of the investigational compound volasertib in the treatment of hematologic malignancies....
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news